A s bstract. Measurement of mevalonic acid (MVA) concentrations in plasma or 24-h urine samples is shown to be useful in studies of the regulation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and cholesterol synthesis. Plasma MVA concentrations, measured either at 7-9 a.m. after an overnight fast, or throughout the 24-h cycle, were compared with cholesterol synthesis rates that were measured by the sterol balance method: plasma MVA concentrations were directly related to the rate of whole body cholesterol synthesis (r = 0.972; p < 0.001; n = 18) over a tenfold range of cholesterol synthesis rates. Moreover, hourly examination of MVA concentrations throughout the day demonstrated that interventions such as fasting or cholesterol feeding cause suppression of the postmidnight diurnal rise in plasma MVA concentrations, with little change in the base-line of the rhythm. Thus, the daily rise and fall of plasma MVA appears to reflect changes in tissues and organs, such as the liver and intestine, that are known to be most sensitive to regulation by fasting or by dietary cholesterol.
Introduction
The biological mechanisms that regulate cholesterol metabolism and maintain cholesterol homeostasis often oppose dietary, pharmacological, or surgical interventions that are aimed at lowering plasma cholesterol levels (1, 2) . Because most of the cholesterol in man arises by de novo synthesis (3) , interest has focused on understanding the mechanisms of regulation of the rate-limiting enzyme of this metabolic pathway, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)' reductase (mevalonate:NADP oxidoreductase [acylating CoA], EC 1.1.1.34), and on the development of inhibitors as pharmacological agents for limiting cholesterol production and lowering plasma cholesterol levels in hypercholesterolemic patients.
HMG-CoA reductase activity is usually measured in vitro by quantitating the rate of formation of mevalonic acid (MVA) from radioactive HMG-CoA. However, MVA can be detected in the blood plasma (4, 5) in concentrations that shift in parallel with changes in liver HMG-CoA reductase in the rat (5) , and with changes in whole body cholesterol synthesis in man (6) . A diurnal rhythm of plasma MVA concentrations has been described in human subjects and shown to be suppressed by dietary cholesterol or fasting (6, 7) . Turnover of labeled MVA is biphasic and rapid (tl/2 < 1 h) in both the rat and man (5, 7) and clearance, primarily by the kidney (8, 9) , but also by the liver and intestine (10) , does not appear to be saturated at physiological concentrations. These observations have led us to the conclusion that plasma MVA concentrations are determined by the balance between MVA input, which is driven by intracellular MVA synthesis in response to factors that regulate HMG-CoA reductase activity, and output, which is mediated by concentration-dependent mechanisms.
We have proposed that the presence in human plasma of MVA, an obligate, rate-limiting precursor of cholesterol, in amounts that are apparently related to the rate of cholesterol synthesis, offers a noninvasive, nonisotopic method for studying the regulation of cholesterol synthesis in man (6) . In the studies presented here, this hypothesis is tested by comparing plasma MVA concentrations and cholesterol synthesis rates under a variety of conditions; the data demonstrate that the two are directly related over a tenfold range of synthesis rates. Through analysis of isotopic MVA kinetics and consideration of the effect of cholesterol feeding on the diurnal MVA rhythm, we explore the possible mechanisms that link plasma MVA and cholesterol synthesis; and by characterizing the effects on MVA concentrations of mevinolin, a specific inhibitor of HMG-CoA reductase (1 1, 12), we demonstrate the usefulness of MVA measurements in clinical studies of cholesterol synthesis.
Methods
Experimental design. Informed consent for designs I, II, and III below were obtained from all in-patients after appropriate review and approval of study protocols by The Rockefeller University Hospital Institutional Review Board. Clinical data and lipid phenotypes for these patients are given in Table I. I. Correlation between cholesterol synthesis and plasma MVA concentrations. Sterol balance studies were carried out on 11 patients (Table I) who were admitted to the metabolic ward at The Rockefeller University Hospital. Except where specifically noted, all patients were maintained solely on liquid formula feeding that was divided into five equal portions and fed to them at 8 a.m. and thereafter at -3-h intervals. Caloric intakes were adjusted to maintain body weights that were constant within ±1.5 kg over study periods of 3-5 wk. The preparation of liquid formula diets and supplementation with vitamins and minerals has been described (13) . The cholesterol content of the formulas was adjusted by dissolving cholesterol (Sigma Chemical Co., St. Louis, MO) after recrystallization from ethanol in the oil phase, during formula preparation.
An adaptation period of at least 2 wk allowed patients to achieve a metabolic steady state, as indicated by constancy of body weight, plasma cholesterol concentration, and daily output of fecal sterols, and a stable clinical course. Stools for sterol balance measurements were collected and analyzed as described elsewhere (14, 15) , with chromic oxide (16) and sitosterol (17) as internal standards. Blood samples for routine MVA determination were obtained by venipuncture between 7 and 9 a.m. after an overnight fast.
II. Diurnal variation ofplasma MVA levels. Except where specifically noted, diurnal MVA rhythms were examined after an adaptation period of three or more weeks on the metabolic ward. A heparin lock that had been placed in the antecubital vein allowed patients to move about or sleep while blood samples were drawn throughout the 24 h (6).
III. Plasma MVA kinetics. Daily urinary MVA output was measured in samples that were obtained from 37 patients who were administered mevinolin twice a day for 4 wk in a multicenter, double-blind, placebo-controlled, doseranging study of mevinolin (12) . These patients were healthy male volunteers of mean age 28.6 (18-35) yr, who had plasma cholesterol levels that were between 150 and 300 mg/dl.
Certain data obtained in these drug studies have been reported previously (12) which was modified as previously described (6) . Urine samples were prepared for MVA determination by centrifugation (2,000 X g X 20 min) to remove solids, then sterilized by filtration (Millipore: 0.45 Mum) and assayed as above.
3R [5-3H] MVA was quantitated by incubation of protein-free plasma ultrafiltrates (Amicon CF25 membranes; Amicon Corp., Bedford, MA) with pig liver mevalonate kinase and ATP, followed by chromatography of the products on Dowex I X 8 as described above except that 3RS [5- '4C]MVA (Research Products International Co., Mount Prospect, IL; 39.5 Ci/mol, sp act) was included in the incubation as an internal standard to correct for efficiency of conversion to phosphomevalonate and recovery (assuming 50% 3R[5-'4C]MVA). Column fractions that contained 3H-and 14C-phosphomevalonate were dispersed in scintillant (Hydrofluor, New England Nuclear, Boston, MA) and counted in a Packard (3990) tricarb liquid scintillation spectrometer (Packard Instrument Co., Downers Grove, IL) that was calibrated to correct for efficiency and crossover using an external standard. By this method, 70-80% of the total tritium in protein-free plasma ultrafiltrates was present as 3R [5-3H] MVA and most of the remainder was 3H20 (as isolated by 1yophilization): 3H-labeled lipids that were bound to proteins or carried on plasma lipoproteins were excluded from the plasma ultrafiltrates and did not interfere with determination of 3R[5-3HJMVA.
Mevinolin assay. Mevinolin was quantitated by comparing the degree of inhibition that was produced by mevinolin-containing samples in a standard HMG-CoA reductase assay (19) . Plasma or urine (0.1 ml) were prepared for assay by adding 0.1 ml of methanol followed by centrifugation to remove precipitates. A tested the hypothesis that these variables would be correlated over a broad range of synthesis rates and under a wide variety of conditions. Thus, data collected from individuals who represented groups that had various cholesterol synthesis' rates (i.e., normal weight vs. obese) were pooled with data that was collected from individuals who were studied before and during interventions that were known to alter synthesis rates (i.e. cholestyramine, portacaval anastomosis (PCA), diet), and all data pairs were assumed to have the same degree of statistical independence and were given equal weight.
Regression analysis was also used to test for a relationship between mevinolin dose and 24-h urinary MVA output. In this analysis, a log transformation was used to obtain values of 1, 2, 3, and 4 on the independent variable (dose of mevinolin 0, 6.25, 12.5, 25, and 50 mg b.i.d.). In cases where the results of linear regression analysis were strongly influenced by a small number of data pairs that were clustered far from the sample mean (Tables I and II) , a nonparametric test of correlation, Spearman's rank correlation coefficient (rj), was reported together with the results of regression analysis. Statistical analysis of differences between paired or unpaired means was carried out using t test. Unless otherwise indicated, all data are presented as the mean±SD with the number of determinations given in parentheses.
Results
Correlation between cholesterol synthesis rates and plasma MVA concentrations. We have previously compared plasma MVA concentrations with the rate of whole body cholesterol synthesis, which was measured by sterol balance, in three patients before and during treatment with cholestyramine (6). Table I summarizes these previous results together with new data that was obtained in studies of two patients before and after portacaval anastomosis (20) , in four patients who received various amounts of dietary cholesterol, and in three patients who had high rates of cholesterol synthesis due to obesity. Taken together, these interventions provided a tenfold range of whole body cholesterol synthesis rates for comparison with plasma MVA concentrations. As shown in Fig. 1 , the plasma MVA concentration was linearly related to the rate of cholesterol synthesis over the entire range from 4.7 to 53.2 mg/ kg. d. By linear regression analysis, we found this relationship to be significant (slope = 3.63, intercept = 5.69, r = 0.972, P < 0.001, n = 18; r, = 0.933).
Diurnal variation ofplasma MVA levels. On the basis of the above observations, we conclude that changes measured in plasma MVA at 7-9 a.m. are related meaningfully to variations in the rate of whole body cholesterol synthesis.
However, plasma MVA concentrations are not constant throughout the day, but vary over a two-to fourfold range through each 24-h period, with peak levels occurring between midnight and 4 a.m. (6, 7) . In Fig. 2 we show the patterns of plasma MVA concentrations that were measured in patient HF when he was eating ad lib three times a day as an outpatient, or 5 feedings/d when he was on the metabolic ward. These data demonstrate that plasma MVA concentrations can vary diurnally in free-living adults, much as they do in patients who were studied on the metabolic ward (6) .
In Table II we compare daily whole body cholesterol synthesis rates and the mean concentration of MVA measured throughout a 24-h period in patient HF and two other patients: the two sets of measurements appear to be closely related (slope = 3.5, intercept = 16.6, r = 0.992, P < 0.001, n = 5; rS = 1.0). Thus, changes in whole body cholesterol synthesis are reflected by corresponding changes in plasma MVA which was measured two ways: either at a fixed time of day (7-9 a.m.: mean of four or more days) (Fig. 1) , or as the mean of 24 samples taken hourly through a single day (Table II) Effect of mevinolin on MVA. As a further test of the proposal that plasma MVA levels reflect cholesterol synthesis rates in the whole body, we carried out a series of studies with a specific inhibitor of HMG-CoA reductase, the drug mevinolin (11) . The immediate effect of a single dose of placebo or 100 mg of mevinolin on successive occasions 1 wk apart to a group of five healthy volunteers is shown in Fig. 4 . Although plasma MVA levels fell in the 6-h period after administration of either placebo or mevinolin, the changes observed after placebo (31% decrease) were relatively small and were well within the range of diurnal variations that were described above. In contrast, plasma MVA concentrations were reduced 78% by the administration of mevinolin and were significantly different from those observed after placebo at all times between 2 and 6 h. There was evidence of recovery of plasma MVA to pretreatment levels at 24 h, but additional studies are needed to characterize the kinetics of this process. Fig . 5 demonstrates the time courses of changes in concentrations of mevinolin in plasma after oral doses of 100 or 200 mg in relation to plasma MVA levels; all changes were dose related. The respective maximum and minimum levels occurred between 4 and 6 h after administration of drug; in addition, the 200-mg dose produced higher mevinolin concentrations and lower MVA levels through the entire 24-h period of study.
The rapid lowering of plasma MVA concentrations that was observed in these experiments, which was caused by a drug that was known to inhibit HMG-reductase, is strong evidence that short-term changes in the rate of MVA synthesis in tissues are quickly reflected by corresponding variations in the rate of MVA efflux and plasma concentration. These experiments also suggested to us that single doses of mevinolin had a short-lived effect on MVA production.
As a further study of the effect of mevinolin administration on MVA metabolism, we measured 24-h urinary MVA output as a function of drug dosage, since Kopito and Brunengraber (21) had shown that MVA output into urine is directly related to its concentration in plasma. As seen in Fig. 6 , at the higher dose levels of 25 and 50 mg twice a day, urinary MVA output was decreased relative to that seen in patients who received placebo. These differences were statistically significant, even when the data obtained in three patients who had MVA outputs >2 SD from their respective group means were not excluded (Table III) remaining after the outliers' were excluded: n = 35, slope =-0.345, intercept = 2.00, r = 0.430, and P < 0.02. Mevinolin, MVA, and cholesterol lowering. To examine the relationship between the effect of mevinolin on MVA and its ability to lower plasma low density lipoprotein (LDL) levels, we plotted the change in MVA and LDL for groups that received placebo, or 6.25, 12.5, 25, and 50 mg of mevinolin twice daily (Fig. 7) . Increasing doses of mevinolin produced steadily decreasing 24-h urinary outputs of MVA, but changes in plasma LDL cholesterol levels reached a plateau at doses of 6.25 mg twice daily. Therefore, in healthy subjects without FH a near-maximal LDL lowering by mevinolin was achieved with doses that only moderately reduced MVA synthesis. of plasma MVA concentrations and 24-h urinary MVA excretions. The regression line that is shown in Fig. 1 predicts that plasma MVA concentrations decrease at very low rates of cholesterol synthesis, but not to zero. Extrapolation to the intercept at zero cholesterol synthesis by linear regression analysis predicts plasma MVA concentrations of 5.7±4.8 nM (P < 0.2), when all data in Table I are included, and 16.2±5.6 nM (P < 0.2) when the highest cholesterol synthesis rates are excluded (cholestyramine periods of patients PW and RM). Although we cannot accept or reject the hypothesis of a nonzero intercept on the basis of available data, continuing MVA production in the absence of net sterol synthesis could have been anticipated from studies in cultured cells that have * Individual values that differed from the group mean by two or more standard deviations were excluded (see n, which equals number of patients for each group). * Significantly different from the placebo group (P < 0.05; t test). § Significantly different from the placebo group (P < 0.025; t test). shown that MVA synthesis cannot be fully suppressed by cholesterol alone: MVA synthesis is regulated to assure a continuing supply of ubiquinone, isopentenyl adenine, dolichols, and other nonsterol products that are derived from MVA (22) . Other explanations of the nonzero intercept must also be considered. Net daily secretion by skin of squalene and sterols that are derived from MVA, which is estimated to be <5% of total body cholesterol production (23), is not routinely included in measurements of whole body cholesterol production that are carried out by the sterol balance method. However, if MVA that was made in the metabolically active cells of the skin had access to the plasma compartment, even though the sterol made by the skin does not fully exchange with plasma cholesterol (24) , this might explain the nonzero intercept.
Discussion
Plasma MVA rhythm. The current studies of diurnal changes in plasma MVA concentrations extend the previous observations of Kopito and Brunengraber (7) and ourselves (6) by demonstrating that such rhythms can occur in freeliving adults. Moreover, the study of patient HF, in which we observed a nearly complete suppression of the midnight rise in plasma MVA concentrations (Fig. 2) , a lowering of the 24-h mean MVA level, and a corresponding reduction in cholesterol production (Table II) The extent to which MVA measurements can substitute for sterol balance measurements remains unclear. The sterol balance method provides a direct quantitative measurement of average daily cholesterol production, as well as information regarding sterol and bile acid metabolism. Quantitation of cholesterol synthesis from MVA measurements is indirect: plasma MVA concentrations that are measured between 7 and 9 a.m. after an overnight fast, 24-h mean plasma MVA concentration, or 24-h urinary MVA outputs are translated into estimates of cholesterol synthesis by use of a calibration curve such as that shown in Fig. 1 . Application of this procedure is based on several assumptions, two of the most important being that within narrow limits, from one subject to the next, the same fraction of total cellular MVA production must escape into plasma, and that renal function and hence MVA clearance and excretion is normal. These assumptions must be shown to be true for each new clinical state before MVA data can be used to infer absolute rates of cholesterol synthesis.
Certainly, MVA measurements can be used to document two-to threefold changes in cholesterol synthesis, such as seen after PCA or administration of cholestyramine: smaller changes in cholesterol synthesis are detectable under controlled circumstances, such as those attained on the metabolic ward. In outpatient studies, where random variations in the timing of the diurnal rhythm are likely to increase the coefficient of variation in measurements of plasma MVA, useful information can be obtained from measurements of 24-h MVA outputs (see Table III and Fig. 5 ). Where the collection of 24-h urine pools is difficult or impossible, plasma MVA concentrations that are measured in control and experimental periods may be compared and expressed as relative change. This experimental design allows the patient to serve as his own control, and thereby reduces error from sources such as differences in MVA transport or catabolism between individuals. We anticipate that MVA transport or catabolism will differ substantially from normal in some disease states, and may obscure the relationship between MVA and cholesterol synthesis that was demonstrated here. We therefore recommend that plasma or urinary MVA data be compared with sterol balance in each new patient group or disease state before conclusions regarding synthesis are drawn from MVA data alone.
